Orkla ASA : Underpinned by a support level
Entry price | Target | Stop-loss | Potential |
---|
NOK 75.76 |
NOK 80 |
NOK 73 |
+5.6% |
---|
The medium term support area around 74.4 NOK should allow Orkla ASA shares to re-establish an upward trend in the short term.
Summary● The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
● Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
● The company's Refinitiv ESG score, based on a ranking of the company relative to its industry, comes out particularly well.
Strengths● Over the past year, analysts have regularly revised upwards their sales forecast for the company.
● Over the past twelve months, analysts' opinions have been strongly revised upwards.
● Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
Weaknesses● The overall consensus opinion of analysts has deteriorated sharply over the past four months.
● The group usually releases earnings worse than estimated.
The content herein constitutes a general investment recommendation, prepared in accordance with provisions aimed at preventing market abuse by Surperformance, the publisher of MarketScreener.com. More specifically, this recommendation is based on factual elements and expresses a sincere, complete, and balanced opinion. It relies on internal or external data, considered reliable as of the date of their release. Nevertheless, this information, and the resulting recommendation, may contain inaccuracies, errors, or omissions, for which Surperformance cannot be held responsible. This recommendation, which in no way constitutes investment advice, may not be suitable for all investor profiles. The reader acknowledges and accepts that any investment in a financial instrument involves risks, for which they assume full responsibility, without recourse against Surperformance. Surperformance commits to disclosing any conflict of interest that may affect the objectivity of its recommendations.